Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 84Terminated 19Withdrawn 6Unknown 3Active not recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Endometrial Neoplasms 1Breast Neoplasms 1Breast Cancer Organoids 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × ixabepilone × Clear all
NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

Xijing Hospital

Unknown
300 enrolled
Breast

Breast Cancer Organoids

NCT00049244 2017-01-30

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

R-Pharm

Phase 1 Unknown
Breast

Breast Neoplasms

NCT01454479 2011-10-19

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Chang Gung Memorial Hospital

Phase 1 Unknown
24 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡